The protective effect of Sirt2 deletion in the p53 heterozygous background was further supported by the observation that HFD Sirt2−/−; p53+/− mice, relative to p53+/− mice, exhibited increased survival (HFD: Sirt2−/−; p53+/− vs. p53+/−p = 0.03) and decreased tumor incidence (HFD: Sirt2−/−; p53+/− vs. p53+/−p = 0.01). Here, TP53 is linked to neoplasm.